NLRP3 and asthma: Here, we show that systemic immune cells from all patients with asthma, both severe and non-severe asthmatics that contain both eosinophilic and non-eosinophilic populations, have an increased ability for nigericin-induced NLRP3 inflammasome activation compared to those from non-asthma subjects (Fig. 1D).